cosmetic weight loss glp 1 GLP-1 Effects on Aesthetic Surgery Trends In early 2025, the AAFPRS

What It Targets Our Tesamorelin + Ipamorelin peptide blendis designed to target: Visceral and central abdominal fat that resists diet and exercise and is linked to cardiometabolic risk. Skinny fat or soft midsections where clients want more definition, not just scale loss. Loss of lean muscle mass, slower recovery, and reduced training capacity in busy, highoutput adults. Metabolic issues such as insulin resistance, unfavorable lipids, or agerelated abdominal obesity in clients already working on lifestyle

Protein shakes designed for GLP-1 users and supplements for peptide therapy can help hit these targets even when appetite is severely suppressed

K., Adamec, J

Jama 327 (12), 1194

The initial dose of amlodipine was 5 mg for 2 weeks with forced titration to 10 mg for 2 weeks, followed by the optional addition of hydrochlorothiazide 12.5 mg for 4 weeks